首页 | 本学科首页   官方微博 | 高级检索  
检索        


Physiological organization of immune response based on the homeostatic mechanism of matrix reprogramming: Implication in tumor and biotechnology
Institution:1. Moscow State University of Medicine and Dentistry, Delegatskaya Str. 20/1, Moscow 127473, Russia;2. Institute of General Pathology and Pathophysiology, Baltijskaya 8, Moscow 125315, Russia;3. University of North Texas Health Science Center, 3500 Camp Bowie Blvd., Fort Worth, TX 76107, USA;4. Moscow State University, GSP-1, Leninskie Gory Str., Moscow 119991, Russia
Abstract:It is accepted that the immune system responds to pathogens with activation of antigen-independent innate and antigen-dependent adaptive immunity. However many immune events do not fit or are even inconsistent with this notion. We developed a new homeostatic model of the immune response. This model consists of four units: a sensor, a regulator, an effector and a rehabilitator. The sensor, macrophages or lymphocytes, recognize pathogenic cells and generate alarm signals. The regulator, antigen-presenting cells, Тregs and myeloid-derived suppressor cells, evaluate the signals and together with sensor cells program the effector. The effector, programmed macrophages and lymphocytes, eliminate the pathogenic cells. The rehabilitator, M2 macrophages, restrict inflammation, provide angiogenesis and reparation of tissue damage, and restore the homeostasis. We suggest the terms “immune matrix” for a biological template of immune responses to pathogens and “matrix reprogramming” for the interdependent reprogramming of different cells in the matrix. In an adequate immune response, the matrix forms a negative feedback mechanism to support the homeostasis. We defined the cellular and phenotypic composition of a tumor immune matrix. A tumor reprograms the homeostatic negative feedback mechanism of matrix into a pathogenic positive feedback mechanism. M2 macrophages play a key role in this transformation. Therefore, macrophages are an attractive target for biotechnology. Based on our hypotheses, we are developing a cell biotechnology method for creation of macrophages with a stable antitumor phenotype. We have shown that such macrophages almost doubled the survival time of mice with tumor.
Keywords:APC"}  {"#name":"keyword"  "$":{"id":"k0375"}  "$$":[{"#name":"text"  "_":"antigen-presenting cell  MHC-I and MHC-II"}  {"#name":"keyword"  "$":{"id":"k0385"}  "$$":[{"#name":"text"  "_":"major histocompatibility complex molecules class I and II  respectively  NK cells"}  {"#name":"keyword"  "$":{"id":"k0395"}  "$$":[{"#name":"text"  "_":"natural killer cells  T  Th0  Th1 and Th2"}  {"#name":"keyword"  "$":{"id":"k0405"}  "$$":[{"#name":"text"  "_":"Т  Th0  Th1 and Th2 cells  respectively  CD"}  {"#name":"keyword"  "$":{"id":"k0415"}  "$$":[{"#name":"text"  "_":"cluster of differentiation  М1 and М2"}  {"#name":"keyword"  "$":{"id":"k0425"}  "$$":[{"#name":"text"  "_":"macrophages of М1 and М2 phenotypes  respectively  COPD"}  {"#name":"keyword"  "$":{"id":"k0435"}  "$$":[{"#name":"text"  "_":"chronic obstructive pulmonary disease  IL"}  {"#name":"keyword"  "$":{"id":"k0445"}  "$$":[{"#name":"text"  "_":"interleukin  TNF-α"}  {"#name":"keyword"  "$":{"id":"k0455"}  "$$":[{"#name":"text"  "_":"tumor necrosis factor-α  IFN-γ"}  {"#name":"keyword"  "$":{"id":"k0465"}  "$$":[{"#name":"text"  "_":"interferon-γ  TGF-β"}  {"#name":"keyword"  "$":{"id":"k0475"}  "$$":[{"#name":"text"  "_":"transforming growth factor-β  ROS"}  {"#name":"keyword"  "$":{"id":"k0485"}  "$$":[{"#name":"text"  "_":"reactive oxygen species  NO"}  {"#name":"keyword"  "$":{"id":"k0495"}  "$$":[{"#name":"text"  "_":"nitric oxide  TLR"}  {"#name":"keyword"  "$":{"id":"k0505"}  "$$":[{"#name":"text"  "_":"toll-like receptor  CTL"}  {"#name":"keyword"  "$":{"id":"k0515"}  "$$":[{"#name":"text"  "_":"cytotoxic antigen-specific Т cells  Treg"}  {"#name":"keyword"  "$":{"id":"k0525"}  "$$":[{"#name":"text"  "_":"CD4+CD25+ T regulatory cells  MDSC"}  {"#name":"keyword"  "$":{"id":"k0535"}  "$$":[{"#name":"text"  "_":"myeloid-derived suppressor cell  TAM"}  {"#name":"keyword"  "$":{"id":"k0545"}  "$$":[{"#name":"text"  "_":"tumor-associated macrophages  HSP70"}  {"#name":"keyword"  "$":{"id":"k0555"}  "$$":[{"#name":"text"  "$$":[{"#name":"__text__"  "_":"heat shock protein with molecular weight 70"}  {"#name":"hsp"  "$":{"sp":"0  25"}}  {"#name":"__text__"  "_":"kDa  EGF"}  {"#name":"keyword"  "$":{"id":"k0575"}  "$$":[{"#name":"text"  "_":"epidermal growth factor  PDGF"}  {"#name":"keyword"  "$":{"id":"k0585"}  "$$":[{"#name":"text"  "_":"platelet-derived growth factor  HGF"}  {"#name":"keyword"  "$":{"id":"k0595"}  "$$":[{"#name":"text"  "_":"hepatocyte growth factor  bFGF"}  {"#name":"keyword"  "$":{"id":"k0605"}  "$$":[{"#name":"text"  "_":"basic fibroblast growth factor  MMP"}  {"#name":"keyword"  "$":{"id":"k0615"}  "$$":[{"#name":"text"  "_":"matrix metalloproteinase  MIF"}  {"#name":"keyword"  "$":{"id":"k0625"}  "$$":[{"#name":"text"  "_":"macrophage migration inhibitory factor  EMMPRIN"}  {"#name":"keyword"  "$":{"id":"k0635"}  "$$":[{"#name":"text"  "_":"extracellular matrix metalloproteinase inducer  CSF-1"}  {"#name":"keyword"  "$":{"id":"k0645"}  "$$":[{"#name":"text"  "_":"macrophage colony-stimulating factor 1  VEGF"}  {"#name":"keyword"  "$":{"id":"k0655"}  "$$":[{"#name":"text"  "_":"vascular endothelial growth factor  G-CSF"}  {"#name":"keyword"  "$":{"id":"k0665"}  "$$":[{"#name":"text"  "_":"granulocyte colony-stimulating factor  GM-CSF"}  {"#name":"keyword"  "$":{"id":"k0675"}  "$$":[{"#name":"text"  "_":"granulocyte–macrophage colony-stimulating factor  uPAR"}  {"#name":"keyword"  "$":{"id":"k0685"}  "$$":[{"#name":"text"  "_":"urokinase-type plasminogen activator receptor  uPA"}  {"#name":"keyword"  "$":{"id":"k0695"}  "$$":[{"#name":"text"  "_":"urokinase-type plasminogen activator  HAF"}  {"#name":"keyword"  "$":{"id":"k0705"}  "$$":[{"#name":"text"  "_":"human angiogenic factor  HIF-1"}  {"#name":"keyword"  "$":{"id":"k0715"}  "$$":[{"#name":"text"  "_":"hypoxia-inducible factor
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号